CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey
The emergence of a new class of drugs – inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) – has changed the paradigm of treatment of patients with luminal HER2 negative metastatic breast cancer. Their effectiveness is confirmed not only by randomized, but also observational studies on a wide heter...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-01-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/765 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399146034757632 |
|---|---|
| author | E. V. Artamonova E. I. Kovalenko L. V. Bolotina M. B. Stenina R. V. Orlova M. A. Mukhina |
| author_facet | E. V. Artamonova E. I. Kovalenko L. V. Bolotina M. B. Stenina R. V. Orlova M. A. Mukhina |
| author_sort | E. V. Artamonova |
| collection | DOAJ |
| description | The emergence of a new class of drugs – inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) – has changed the paradigm of treatment of patients with luminal HER2 negative metastatic breast cancer. Their effectiveness is confirmed not only by randomized, but also observational studies on a wide heterogeneous population of patients from daily clinical practice; the use of these drugs in the 1st line is significantly expanding in the world. On the territory of the Russian Federation, an observational study of Prometheus was carried out, the purpose of which was to assess the frequency of prescribing CDK4/6 inhibitors, as well as other types of treatment in 1–2nd lines in real clinical practice in Russia, as well as factors and preferences of doctors influencing the choice of therapy. A survey of the target audience, whose answers can be considered reliable and reflecting today’s Russian clinical practice in the treatment of breast cancer, showed that, despite the fact that the overwhelming majority of doctors (78 %) believe that the maximum benefit from the appointment of CDK4/6 inhibitors is expected for the 1st line therapy, in real clinical practice, only 35 % of doctors practice 1 st line prescription. In the 2nd line of therapy, CDK4/6 inhibitors are prescribed by 45 % of experts, in the 3rd (or more) line – 20 %. According to the respondents, the main obstacle to the appointment of CDK4/6 inhibitors is the unresolved issues of the availability of therapy (44 %) and its cost (34 %). Among all the proposed clinical criteria, only the criterion “visceral metastases with impaired function of internal organs” influences the decision not to prescribe a combination of hormonal therapy and a CDK4/6 inhibitor in 1–2nd lines of therapy. Criteria such as ECOG status, menopause status, tumor subtype preceding chemotherapy, timing of progression do not determine the choice when deciding not to prescribe combination therapy. |
| format | Article |
| id | doaj-art-640a20fdf7f74bcf91ba6e8ec246f550 |
| institution | Kabale University |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2021-01-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-640a20fdf7f74bcf91ba6e8ec246f5502025-08-20T03:38:24ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272021-01-01163374510.17650/1994-4098-2020-16-3-37-45657CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the surveyE. V. Artamonova0E. I. Kovalenko1L. V. Bolotina2M. B. Stenina3R. V. Orlova4M. A. Mukhina5N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Department of Oncology and Radiation Therapy, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Oncology and Thoracic Surgery, M.F. Vladimirsky Moscow Regional Research and Clinical InstituteN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaP.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaSaint-Petersburg State University; City Clinical Oncological DispensaryPfizer Innovations LLCThe emergence of a new class of drugs – inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) – has changed the paradigm of treatment of patients with luminal HER2 negative metastatic breast cancer. Their effectiveness is confirmed not only by randomized, but also observational studies on a wide heterogeneous population of patients from daily clinical practice; the use of these drugs in the 1st line is significantly expanding in the world. On the territory of the Russian Federation, an observational study of Prometheus was carried out, the purpose of which was to assess the frequency of prescribing CDK4/6 inhibitors, as well as other types of treatment in 1–2nd lines in real clinical practice in Russia, as well as factors and preferences of doctors influencing the choice of therapy. A survey of the target audience, whose answers can be considered reliable and reflecting today’s Russian clinical practice in the treatment of breast cancer, showed that, despite the fact that the overwhelming majority of doctors (78 %) believe that the maximum benefit from the appointment of CDK4/6 inhibitors is expected for the 1st line therapy, in real clinical practice, only 35 % of doctors practice 1 st line prescription. In the 2nd line of therapy, CDK4/6 inhibitors are prescribed by 45 % of experts, in the 3rd (or more) line – 20 %. According to the respondents, the main obstacle to the appointment of CDK4/6 inhibitors is the unresolved issues of the availability of therapy (44 %) and its cost (34 %). Among all the proposed clinical criteria, only the criterion “visceral metastases with impaired function of internal organs” influences the decision not to prescribe a combination of hormonal therapy and a CDK4/6 inhibitor in 1–2nd lines of therapy. Criteria such as ECOG status, menopause status, tumor subtype preceding chemotherapy, timing of progression do not determine the choice when deciding not to prescribe combination therapy.https://ojrs.abvpress.ru/ojrs/article/view/765metastatic breast cancercdk4/6 inhibitorspalbociclibrussian clinical practice |
| spellingShingle | E. V. Artamonova E. I. Kovalenko L. V. Bolotina M. B. Stenina R. V. Orlova M. A. Mukhina CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey Опухоли женской репродуктивной системы metastatic breast cancer cdk4/6 inhibitors palbociclib russian clinical practice |
| title | CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey |
| title_full | CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey |
| title_fullStr | CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey |
| title_full_unstemmed | CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey |
| title_short | CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey |
| title_sort | cdk4 6 inhibitors in the treatment of metastatic breast cancer choosing optimal therapy for estrogen receptor positive her2 negative metastatic breast cancer analysis of doctors preferences prometheus in russia first results of the survey |
| topic | metastatic breast cancer cdk4/6 inhibitors palbociclib russian clinical practice |
| url | https://ojrs.abvpress.ru/ojrs/article/view/765 |
| work_keys_str_mv | AT evartamonova cdk46inhibitorsinthetreatmentofmetastaticbreastcancerchoosingoptimaltherapyforestrogenreceptorpositiveher2negativemetastaticbreastcanceranalysisofdoctorspreferencesprometheusinrussiafirstresultsofthesurvey AT eikovalenko cdk46inhibitorsinthetreatmentofmetastaticbreastcancerchoosingoptimaltherapyforestrogenreceptorpositiveher2negativemetastaticbreastcanceranalysisofdoctorspreferencesprometheusinrussiafirstresultsofthesurvey AT lvbolotina cdk46inhibitorsinthetreatmentofmetastaticbreastcancerchoosingoptimaltherapyforestrogenreceptorpositiveher2negativemetastaticbreastcanceranalysisofdoctorspreferencesprometheusinrussiafirstresultsofthesurvey AT mbstenina cdk46inhibitorsinthetreatmentofmetastaticbreastcancerchoosingoptimaltherapyforestrogenreceptorpositiveher2negativemetastaticbreastcanceranalysisofdoctorspreferencesprometheusinrussiafirstresultsofthesurvey AT rvorlova cdk46inhibitorsinthetreatmentofmetastaticbreastcancerchoosingoptimaltherapyforestrogenreceptorpositiveher2negativemetastaticbreastcanceranalysisofdoctorspreferencesprometheusinrussiafirstresultsofthesurvey AT mamukhina cdk46inhibitorsinthetreatmentofmetastaticbreastcancerchoosingoptimaltherapyforestrogenreceptorpositiveher2negativemetastaticbreastcanceranalysisofdoctorspreferencesprometheusinrussiafirstresultsofthesurvey |